Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - fulvestrant 250 mg - solution for injection in pre-filled syringe - fulvestrant

Հորդանան - անգլերեն - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية الصباغ - sabbagh drug store - fulvestrant 250 mg/5ml - 250 mg/5ml

Հարավաֆրիկյան Հանրապետություն - անգլերեն - South African Health Products Regulatory Authority (SAHPRA)

mylan pharmaceuticals (pty) ltd - #n/a - not indicated - none

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

astrazeneca limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - breast neoplasms - endocrine therapy, anti-estrogens - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy., , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , in pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.,

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

multichem nz limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Կանադա - անգլերեն - Health Canada

astrazeneca canada inc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - fulvestrant - solution for injection - 50mg/1ml

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

euro asia medico pte. ltd. - fulvestrant - injection, solution - fulvestrant 250mg / 5ml